Investors
OMX Stockholm
( %)
HNSA SEK
Some content on this page is only available in English. All material required under applicable law, regulation or code is available in English and Swedish.
Calendar
Upcoming events
22Jul
Interim Report for January-June 2026
05Nov
Interim Report for January-September 2026
Press releases
Our latest press releases
Hansa Biopharma to host Q2 2026 interim results conference call
08/07/2026
Hansa Biopharma participating in Wedbush PacGrow Renal Summit
02/07/2026
Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
Regulatory press release
01/07/2026
Hansa Biopharma announces ConfIdeS Phase 3 Abstract Selected for ‘What’s Hot, What’s New’ Plenary at ATC 2026
24/06/2026
Hansa Biopharma in brief
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
